The U.S. Food and Drug Administration has issued a draft guidance document on the proposed select updates for the Breakthrough Devices Program guidance.
Once finalized, the guidance document updates would expand the Breakthrough Devices Program’s scope to include devices that will improve accessibility and promote health equity.
Specifically, the draft guidance clarifies the considerations in designating devices, including devices that may benefit populations impacted by disparities in health and healthcare. The document also includes discussions how the FDA intends to disclose the Breakthrough Device status once the device obtains marketing authorization for an indication for use consistent with its Breakthrough Device designation.
Read the full article on Emergo by UL’s blog.
The opinions expressed in this post are the author’s only and do not necessarily reflect those of MedicalDesignandOutsourcing.com or its employees.
